Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia (TASKPEN)
Primary Purpose
Non Communicable Diseases, HIV
Status
Recruiting
Phase
Not Applicable
Locations
Zambia
Study Type
Interventional
Intervention
TASKPEN
Sponsored by
About this trial
This is an interventional other trial for Non Communicable Diseases focused on measuring HIV, Non Communicable Diseases, WHO-PEN
Eligibility Criteria
Objective 1
Focus group discussion participants/implementation survey participants:
Inclusion:
- 18 years of age or older
- non-physician professional or lay/peer health care worker (HCW) involved with HIV and/or NCD service delivery.
Key Informant Interview (KII) participants:
- 18 years of age or older
- a senior Ministry of Health (MOH) policy maker or health official working at national level in Zambia involved in managing, coordinating, and/or overseeing health services for non-communicable diseases in Zambia.
In-depth interview participants:
- emancipated HIV-infected adults 18 years of age or older have a documented cardio-metabolic condition
Exclusion:
- any potential IDI, FGD, or KII participant if they are unwilling or unable to provide informed consent.
Objective 2:
Cross-sectional assessments:
Inclusion:
- HIV-infected
- aged 18 years and older
- seeking care at either of the two ACHIEVE-supported pilot sites who are screened for and/or found to have evidence of one or more of the cardio-metabolic conditions or risk factors.
Nested cohort participants:
Inclusion:
- documented HIV infection
- aged 18 years or older
have one or more cardio-metabolic conditions or risk factors:
- obesity (defined as BMI > 30 kg/m^2);
- any current tobacco smoking;
- hypertension as defined by WHO PEN (i.e., systolic blood pressure (SBP) = 140 mmHg and/or diastolic blood pressure (DBP) = 90 mmHg);
- diabetes mellitus as defined by WHO PEN (i.e. random plasma glucose = 11.1 mmol/L, fasting plasma glucose = 7 mmol/L, and/or haemoglobin A1c = 48 mmol/mol);
- prediabetes (defined as having impaired fasting glucose of 6.1 to 6.9 mmol/L, impaired glucose tolerance with a two-hour, post-oral glucose tolerance test glucose =7.8 mmol/L but <11.1 mmol/L and a fasting plasma glucose <7.0 mmol/L, and/or haemoglobin A1c 42 to 48 mmol/mol); 6) dyslipidaemia (defined as total cholesterol >4 mmol/L or low density lipoprotein =6 mmol/L); and/or 7) personal history or medication use for heart disease, heart failure, stroke, or other cardio-metabolic complication (including but not limited to coronary artery disease, cerebrovascular disease, myocardial infarction, stroke, or peripheral vascular disease).
IDI participants:
- HIV-infected
- 18 years of age who were enrolled in the nested cohort and had documented exposure to the TASKPEN intervention at a pilot site.
FGD participants:
- 18 years of age or older
- a non physician health care worker (NPHW) or community health worker (CHW)/ lay health provider involved with TASKPEN or integrated HIV/NCD service delivery generally familiar with HIV and/or NCD service delivery at their facility.
KII participants:
- 18 years of age or older
- a facility-level antiretroviral therapy (ART) or out-patient department (OPD) clinic manager/ in-charge or policy maker at district, provincial, or national level in Zambia; and generally familiar with HIV and/or NCD-related issues in their community.
Exclusion criteria:
For the nested cohort component, investigators will exclude:
- adults who have no documented evidence of having established HIV care at the sites.
- people unlikely to remain at the site to the completion of the study follow-up.
- any potential IDI, FGD, or KII participant if they are unwilling or unable to provide written informed consent.
Sites / Locations
- Chawama 1st Level hospitalRecruiting
- Chilenje 1st level hospitalRecruiting
- George urban health centerRecruiting
- Mtendere health centerRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TASKPEN
Arm Description
a package of integrated HIV/NCD services
Outcomes
Primary Outcome Measures
Change in percent of participants with dual HIV and NCD disease control
measured by an HIV RNA level of <200 copies per milliliter on the most recent measure and systolic blood pressure <140 mmHg on most recent measure, hemoglobin A1c <7.0% on most recent measure, and/or total cholesterol <5.2 mmol/L
ASCVD risk score
Measured by % of participants who experienced improvement in ASCVD risk score between baseline and follow up (e.g. from intermediate to borderline risk category)
Secondary Outcome Measures
Changes in HIV disease control, as measured by the % of patients with HIV RNA suppression (defined as <1,000 copies/mL)
measured by the % of patients with HIV RNA suppression (defined as <1,000 copies/mL)
Changes in quality of life, as measured by the standardized World Health Organization HIV Quality of Life questionnaire (brief version)
User and provider feedback. The WHOQOL-BREF measures quality of life across 4 domains (Physical Health, Psychological, Social Relationships, and Environment). The minimum score is 0 and maximum is 100. Higher scores correspond to greater perceived quality of life.
Change in Intervention Reach
Proportion of the health care providers accepting to implement the TASKPEN intervention at pilot health facilities
Change in Intervention appropriateness
The "Intervention appropriateness measure (IAM)" among health care providers. The minimum score is 1 and maximum is 5. Higher scores indicate greater appropriateness.
Change in Intervention Acceptability
Measured by the "Acceptability of Intervention measure (AIM)" among health care providers The minimum score is 1 and maximum is 5. Higher scores indicate greater appropriateness.
Change in Intervention Feasibility
measured by the "Feasibility of Intervention Measure (FIM)" among health care providers.
The minimum score is 1 and maximum is 5. Higher scores indicate greater feasibility.
Intervention Cost
measured by cost per patient treated with the TASKPEN intervention
Full Information
NCT ID
NCT05005130
First Posted
July 19, 2021
Last Updated
February 17, 2022
Sponsor
University of North Carolina, Chapel Hill
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Centre for Infectious Disease Research in Zambia, University of Zambia, Ministry of Health, Zambia, University of Alabama at Birmingham, Fogarty International Center of the National Institute of Health
1. Study Identification
Unique Protocol Identification Number
NCT05005130
Brief Title
Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia
Acronym
TASKPEN
Official Title
Mixed Methods Formative Research and Pilot Testing of a Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 20, 2021 (Actual)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
July 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Centre for Infectious Disease Research in Zambia, University of Zambia, Ministry of Health, Zambia, University of Alabama at Birmingham, Fogarty International Center of the National Institute of Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This mixed-methods formative research study aims to adapt the WHO Package of Essential Noncommunicable Disease Interventions (WHO-PEN) approach for the Zambian public health system, and pilot test an adapted, streamlined, and task-shifted package of integrated HIV Noncommunicable Disease (NCD) services, collectively called "TASKPEN".
Detailed Description
Using local data and implementation science theories WHO-PEN will be adapted for Zambia, and TASKPEN developed to focus on addressing challenges faced by persons living with HIV (PLHIV) who have cardio-metabolic complications related to HIV or its treatment (e.g. hypertension, diabetes, dyslipidaemia). TASKPEN aims to improve detection and management of these complications.
Formative research activities for objective 1 include focus group discussions (FGDs), surveys and interviews with key stakeholders, which will include in-depth interviews (IDIs) with patients.
Objective 2 launches the TASKPEN pilot and fully task-shifts the TASKPEN package to non-physician healthcare workers (NPHWs) and integrates it within the President's Emergency Plan for AIDS Relief (PEPFAR) -supported HIV service delivery platform. A mix of IDIs, FGDs, key informant interviews, and patient and implementation surveys with implementation actors to evaluate feasibility, acceptability, and other implementation outcomes
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Communicable Diseases, HIV
Keywords
HIV, Non Communicable Diseases, WHO-PEN
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol.
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TASKPEN
Arm Type
Experimental
Arm Description
a package of integrated HIV/NCD services
Intervention Type
Other
Intervention Name(s)
TASKPEN
Intervention Description
The package of integrated HIV/NCD services:
WHO PEN protocols, algorithm, & training materials adapted for Zambia
Access to cardio-metabolic condition screening & laboratory monitoring
Non communicable disease-focused electronic medical record module
Integrated non-communicable/HIV care ("one stop shop" for services)
Trained non-physician providers able to provide integrated care
Primary Outcome Measure Information:
Title
Change in percent of participants with dual HIV and NCD disease control
Description
measured by an HIV RNA level of <200 copies per milliliter on the most recent measure and systolic blood pressure <140 mmHg on most recent measure, hemoglobin A1c <7.0% on most recent measure, and/or total cholesterol <5.2 mmol/L
Time Frame
Baseline to 6 months
Title
ASCVD risk score
Description
Measured by % of participants who experienced improvement in ASCVD risk score between baseline and follow up (e.g. from intermediate to borderline risk category)
Time Frame
Baseline to 6 months
Secondary Outcome Measure Information:
Title
Changes in HIV disease control, as measured by the % of patients with HIV RNA suppression (defined as <1,000 copies/mL)
Description
measured by the % of patients with HIV RNA suppression (defined as <1,000 copies/mL)
Time Frame
Baseline to 6 months
Title
Changes in quality of life, as measured by the standardized World Health Organization HIV Quality of Life questionnaire (brief version)
Description
User and provider feedback. The WHOQOL-BREF measures quality of life across 4 domains (Physical Health, Psychological, Social Relationships, and Environment). The minimum score is 0 and maximum is 100. Higher scores correspond to greater perceived quality of life.
Time Frame
Baseline to 6 months
Title
Change in Intervention Reach
Description
Proportion of the health care providers accepting to implement the TASKPEN intervention at pilot health facilities
Time Frame
Baseline to 6 months
Title
Change in Intervention appropriateness
Description
The "Intervention appropriateness measure (IAM)" among health care providers. The minimum score is 1 and maximum is 5. Higher scores indicate greater appropriateness.
Time Frame
Baseline to 6 months
Title
Change in Intervention Acceptability
Description
Measured by the "Acceptability of Intervention measure (AIM)" among health care providers The minimum score is 1 and maximum is 5. Higher scores indicate greater appropriateness.
Time Frame
Baseline to 6 months
Title
Change in Intervention Feasibility
Description
measured by the "Feasibility of Intervention Measure (FIM)" among health care providers.
The minimum score is 1 and maximum is 5. Higher scores indicate greater feasibility.
Time Frame
Baseline to 6 months
Title
Intervention Cost
Description
measured by cost per patient treated with the TASKPEN intervention
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Objective 1
Focus group discussion participants/implementation survey participants:
Inclusion:
18 years of age or older
non-physician professional or lay/peer health care worker (HCW) involved with HIV and/or NCD service delivery.
Key Informant Interview (KII) participants:
18 years of age or older
a senior Ministry of Health (MOH) policy maker or health official working at national level in Zambia involved in managing, coordinating, and/or overseeing health services for non-communicable diseases in Zambia.
In-depth interview participants:
emancipated HIV-infected adults 18 years of age or older have a documented cardio-metabolic condition
Exclusion:
any potential IDI, FGD, or KII participant if they are unwilling or unable to provide informed consent.
Objective 2:
Cross-sectional assessments:
Inclusion:
HIV-infected
aged 18 years and older
seeking care at either of the two ACHIEVE-supported pilot sites who are screened for and/or found to have evidence of one or more of the cardio-metabolic conditions or risk factors.
Nested cohort participants:
Inclusion:
documented HIV infection
aged 18 years or older
have one or more cardio-metabolic conditions or risk factors:
obesity (defined as BMI > 30 kg/m^2);
any current tobacco smoking;
hypertension as defined by WHO PEN (i.e., systolic blood pressure (SBP) = 140 mmHg and/or diastolic blood pressure (DBP) = 90 mmHg);
diabetes mellitus as defined by WHO PEN (i.e. random plasma glucose = 11.1 mmol/L, fasting plasma glucose = 7 mmol/L, and/or haemoglobin A1c = 48 mmol/mol);
prediabetes (defined as having impaired fasting glucose of 6.1 to 6.9 mmol/L, impaired glucose tolerance with a two-hour, post-oral glucose tolerance test glucose =7.8 mmol/L but <11.1 mmol/L and a fasting plasma glucose <7.0 mmol/L, and/or haemoglobin A1c 42 to 48 mmol/mol); 6) dyslipidaemia (defined as total cholesterol >4 mmol/L or low density lipoprotein =6 mmol/L); and/or 7) personal history or medication use for heart disease, heart failure, stroke, or other cardio-metabolic complication (including but not limited to coronary artery disease, cerebrovascular disease, myocardial infarction, stroke, or peripheral vascular disease).
IDI participants:
HIV-infected
18 years of age who were enrolled in the nested cohort and had documented exposure to the TASKPEN intervention at a pilot site.
FGD participants:
18 years of age or older
a non physician health care worker (NPHW) or community health worker (CHW)/ lay health provider involved with TASKPEN or integrated HIV/NCD service delivery generally familiar with HIV and/or NCD service delivery at their facility.
KII participants:
18 years of age or older
a facility-level antiretroviral therapy (ART) or out-patient department (OPD) clinic manager/ in-charge or policy maker at district, provincial, or national level in Zambia; and generally familiar with HIV and/or NCD-related issues in their community.
Exclusion criteria:
For the nested cohort component, investigators will exclude:
adults who have no documented evidence of having established HIV care at the sites.
people unlikely to remain at the site to the completion of the study follow-up.
any potential IDI, FGD, or KII participant if they are unwilling or unable to provide written informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chilambwe Mwila, MSc
Phone
260 966 608354
Email
Chilambwe.Mwila@cidrz.org
First Name & Middle Initial & Last Name or Official Title & Degree
Christy Frimpong, MPH
Email
Christiana.Frimpong@cidrz.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Herce, MD, MPH, MSc
Organizational Affiliation
University of North Carolina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wilbroad Mutale, MBChB, MPhil, MPhil, PhD
Organizational Affiliation
Centre for Infectious Disease Research in Zambia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chawama 1st Level hospital
City
Lusaka
Country
Zambia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christy Frimpong
Email
Christiana.Frimpong@cidrz.org
Facility Name
Chilenje 1st level hospital
City
Lusaka
Country
Zambia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christy Frimpong
Email
Christiana.Frimpong@cidrz.org
First Name & Middle Initial & Last Name & Degree
Wilbroad Mutale
Facility Name
George urban health center
City
Lusaka
Country
Zambia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christy Frimpong
Email
Christiana.Frimpong@cidrz.org
First Name & Middle Initial & Last Name & Degree
Wilbroad Mutale
Facility Name
Mtendere health center
City
Lusaka
Country
Zambia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christy Frimpong
Email
Christiana.Frimpong@cidrz.org
First Name & Middle Initial & Last Name & Degree
Wilbroad Mutale
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC
IPD Sharing Time Frame
from 9 to 36 months following publication
IPD Sharing Access Criteria
investigator who proposes to use the data has approval from an IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
Learn more about this trial
Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia
We'll reach out to this number within 24 hrs